Fengqi (Sherry) Zhou, O.D.

I have always had a strong desire to pursue a profession in the health care field since childhood. The immense pleasure and gratification of improving the health and well-being of others appeal to me in an instinctual way. Throughout the years in medical school and optometry school, I have found caring for patients with complex, multifaceted conditions in a multidisciplinary collaborative academic hospital setting to be intellectually challenging and incredibly rewarding. I strive to provide high-quality care using evidence-based medicine to patients of different backgrounds in a compassionate approach. I look forward to building rapport with my patients and making a positive change in their life.

I grew up in Guangzhou (Canton), China, and completed my bachelor's degree in medicine from Sun Yat-Sen University in Guangzhou, China. Towards the end of my first year residency training in ophthalmology at Zhongshan Ophthalmic Center, I decided to leave my comfort zone, and embarked on the journey of pursuing optometry in the U.S. After graduating from New England College of Optometry in Boston, I went on to complete a residency in ocular disease with emphasis on glaucoma and retinal conditions at Indiana University School of Optometry in Bloomington, Indiana.

I am excited about joining the Mayo Clinic family and look forward to the new chapter in my career.

In my spare time, I enjoy spending time travelling, hiking, swimming, and watching movies and documentaries.

Education

• Doctor in Optometry, New England College of Optometry

Residency

• Ocular Disease, Indiana University School of Optometry

Memberships

• American Academy of Optometry
• American Optometric Association

• Dry eye
• Ocular disease

• Novel mutation in OCRL leading to a severe form of Lowe syndrome, 2019.
• Comparative meta-analysis of toric intraocular lens alignment accuracy in cataract patients: Image-guided system versus manual marking, September 2019.
• A safe treatment for congenital fibrovascular pupillary membrane, July 2019.
• A missense mutation in CRYBB2 leads to progressive congenital membranous cataract by impacting the solubility and function of βB2-crystalli, November 2013.